Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Merit Medical (MMSI) to $95 from $103 and keeps an Overweight rating on the shares. The firm notes the company withdrew Wrapsody’s TPT bid after CMS pushed approval to 2027, with management pivoting to full U.S. launch under a new strategy. Missteps have hurt potential Wrapsody upside and management credibility, but strong core business momentum supports Wells’ bullish stance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Systems: Strategic Adjustments and Growth Potential Justify Buy Rating
- Closing Bell Movers: Applied Materials down 4% after earnings and guidance
- Merit Medical Systems Begins WRAPSODY CIE Commercialization
- CMS notifies Merit that Wrapsody reimbursement requires further consideration
- Merit Medical releases 24-month efficacy results from AVF arm of WAVE trial